Bonderman Single Family Office Backs Californian Fertility C

Published: 2025-05-18 Source: Author:
Bonderman Single Family Office Backs Californian Fertility C

Finance Image

Recently, Spring Fertility announced a new funding round of Wildcat Capital Management, the of private equity billionaire David Bonderman, that is featured in our . Spring Fertility offers fertility services and so-called egg freezing. The San Francisco-based company secured a first $3M funding round in 2015. The recent investment of Bonderman’s investment company should advance growth in the bay area and North America.A leader in Fertility Services In San FranciscoSpring Fertility earns its money by helping women to get pregnant. The core offerings are regular fertility services and egg freezing. Within the fertility services, the company deals with finding the reasons for infertility which can lie in four different areas. Egg freezing helps to plan a successful pregnancy later in life by freezing the “best” eggs. Spring Fertility’s services come with a decent price tag: an egg-freezing cycle costs more than $8,750. Additional yearly storage fees occur. Also integrated into Spring Fertility are discounts for veterans, nurses, teachers and firemen as well as the “Giving Back” pledge. The company says that “for every child Spring helps bring into the world, we help women receive skilled & emergency obstetric care in East Africa through Mama Rescue”.Investment of Bonderman Single Family OfficeThe only known investment in this round is of Wildcat Capital Management, the office of David Bonderman. Bonderman is a co-founder of TPG Capital, a Fort-Worth based private equity fund founded in 1993. Today, TPG has assets under management of over $100B. Famous investments of the company include Burger King, Norwegian Cruis Line, Lenovo or Cushman & Wakefield and Airbnb. Now, the successful private equity entrepreneur Sondermann invests via his own single family office. Previous investments of the billionaire already brought big exits: for example, his portfolio company Kite Pharma was sold to Gilead Sciences in 2017. Net profit for Bonderman: $425M.Picture source: Featured €149,99 including VAT Rated 5.00 out of 5 €799,99 including VAT Rated 4.67 out of 5 €499,99 including VAT Rated 4.67 out of 5 €1.499,99 including VAT

User Comments1. Ava Edwards: Comment sample 1...2. Alexander Roberts: Comment sample 2...3. Ava King: Comment sample 3...4. Grace Y.: Comment sample 4...5. Williams, Emily: Comment sample 5...Editor's NoteThis article was refined for clarity, structure, and user experience.

Finance Image

(Editors: admin)